About 468 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  162 results

Acquired Hemophilia A associated with bullous pemphigoid: A rare combination.
Transfusion and Apheresis Science : Official Journal of T... Bragança M, Valente C et. al.

Dec 15th, 2021 - Acquired Hemophilia A (AHA) is a rare autoimmune disorder, caused by the development of circulating autoantibodies against coagulation factor VIII (FVIII). AHA is associated with bullous pemphigoid in 2% of patients. We report a case of a 74-year-...

Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B.
Blood Reviews; Constantinescu C, Jitaru C et. al.

Nov 16th, 2021 - There is a dire need to develop an algorithm to improve the recognition of acquired hemophilia A and B (AHA and AHB) in clinical practice. Initial and intensive care unit (ICU) management of the disorder is particular and represents a challenge fo...

Hemophilia A (Factor VIII Deficiency)

Nov 16th, 2021 - Practice Essentials Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. The development of inhibitory alloantibodies to ...

Acquired Hemophilia

Nov 16th, 2021 - Practice Essentials Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII (FVIII).1 Acquir...

Hemophilia A (Factor VIII Deficiency)

Nov 16th, 2021 - Practice Essentials Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. The development of inhibitory alloantibodies to ...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  2 results

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Aug 5th, 2021 - This study is a multi-center, uncontrolled, open-label, non-interventional post-marketing safety surveillance study to describe the use of Obizur in patients with acquired hemophilia A (AHA), and secondarily, where data are available, to describe ...

Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study

Jun 18th, 2013 - the aims of SACHA study was to appreciate prevalence, evolution and follow-up, treatment response of patients with acquired hemophilia with biological and clinical data. Inclusion criteria were factor VIIIc below 30% associated with presence of Fa...

see more →

News  15 results

Immunoabsorption shows promise as an adjunct treatment for high-risk acquired hemophilia
Mark S. Lesney, PhD

Feb 3rd, 2021 - Despite the high mortality rate for acquired hemophilia and the availability of suggested drug treatments, there are no randomized, controlled studies to inform doctors of the best therapies for their patients. Immunoabsorption therapy (IA) is one.

New consensus recommendations on bleeding in acquired hemophilia
Caleb Rans

Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.

An unusual cause of bruising

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

see more →

Patient Education  1 results see all →